Nilemdo (Bempedoic Acid)

Bempedoic acid, the active ingredient in Nilemdo, is an ATP citrate lyase inhibitor presented as an oral tablet for systemic use. It is indicated as an adjunct to diet and statin therapy for primary hypercholesterolemia and for heterozygous familial hypercholesterolemia in adults.

GNH USA supplies Nilemdo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches, regulatory conformity and reliable logistics for global distribution.

Nilemdo is an ATP citrate lyase inhibitor used to manage disorders of elevated LDL‑cholesterol.

Primary hypercholesterolemia: lowers LDL‑C when added to diet and statin therapy. Heterozygous familial hypercholesterolemia: reduces LDL‑C as adjunct to maximally tolerated statins. Patients requiring additional LDL‑C reduction: provides further cholesterol lowering beyond statins alone.

Nilemdo may cause a range of adverse reactions.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory irritation. - Muscle pain: occasional myalgia without severe injury. - Abdominal discomfort: transient stomach pain or indigestion. - Elevated liver enzymes: mild increases in ALT/AST. - Headache: occasional mild to moderate headache. - Gout flare: increased uric acid may precipitate gout.

Serious or Rare Side Effects: - Tendon rupture: rare but serious musculoskeletal injury. - Rhabdomyolysis: severe muscle breakdown requiring immediate care. - Severe liver injury: marked elevation of hepatic enzymes or hepatitis. - Hypersensitivity reactions: including rash, angioedema, or anaphylaxis. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating Nilemdo, clinicians should consider several safety measures.

Renal function: assess baseline and monitor periodically. Liver enzymes: check ALT/AST before treatment and during therapy. Pregnancy: use only if potential benefit justifies potential risk to fetus. Drug interactions: review concomitant lipid‑lowering agents for additive muscle toxicity. Hyperuricemia: monitor serum uric acid levels, especially in gout‑prone patients. Store at ambient temperature: keep in original container, protect from moisture and light.

Nilemdo can interact with several medications; awareness of interaction severity guides management.

Major Interactions (Avoid): - High‑dose simvastatin (>20 mg): increased risk of myopathy and rhabdomyolysis. - Gemfibrozil: additive muscle toxicity risk.

Moderate Interactions (Monitor Closely): - Other statins (atorvastatin, rosuvastatin): monitor liver enzymes and muscle symptoms. - Warfarin: may alter INR; check coagulation parameters regularly. - Antihypertensive agents: generally no clinically significant interaction, but observe blood pressure trends.